Lyra Therapeutics (LYRA), Monday announced that the phase 3 enlighten trial 1 to evaluate the efficacy and safety of LYR-210 for the treatment of chronic rhinosinusitis or CRS failed to meet the primary endpoint.
CRS is a highly prevalent inflammatory disease of the paranasal sinuses, casuing debilitating symptoms and significant morbidities in people under age 65.
The company stated that the sham-controlled trial failed to show statistically significant improvement compared to the control group in the composite score of the three cardinal symptoms of CRS at 24 weeks.
The biotechnology company further said that data from the 52-week extension phase of the trial is expected in the fourth quarter.Currently, Lyra's stock is moving down 89.91 percent, to $0.40 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.